Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Staphylococcus aureus tyrosyl-tRNA synthetase is an essential bacterial enzyme responsible for linking L-tyrosine to its corresponding tRNA(Tyr) through an ATP-dependent reaction, forming tyrosyl-AMP and subsequently transferring the amino acid to tRNA. This process is fundamental for ribosomal translation and bacterial protein synthesis. TyrRS belongs to the class I aminoacyl-tRNA synthetases, featuring a Rossmann-fold catalytic domain. It has been structurally characterized in complex with several classes of inhibitors, which provided key insights for the development of novel antibiotics. Selective inhibitors of Staphylococcus aureus TyrRS show potent bacteriostatic effects by halting protein synthesis, positioning the enzyme as a promising target in efforts to combat antibiotic resistance in S. aureus infections.
Inhibition of tyrosyl-tRNA synthetase blocks aminoacylation of tRNA(Tyr), halting protein synthesis and thus bacterial growth. Most inhibitors are competitive, binding at or near the active site or substrate-binding domain.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Staphylococcus aureus tyrosyl-tRNA synthetase (TyrRS or tyrS).